Monoclonal antibodies in the treatment of myelogenous leukemias

  • David A. Scheinberg
Part of the Cancer Treatment and Research book series (CTAR, volume 64)

Abstract

Monoclonal antibodies (mAb) differ dramatically from conventional therapeutic agents in their mechanisms of actions and in their biochemical and biological properties [1–3]. On the one hand, mAbs are capable of selective targeting of tumor cells while avoiding normal tissues. MAbs are able to kill tumor cells via a variety of intrinsic (immunological) and extrinsic (by use of carried cytotoxic agents) modes. On the other hand, these molecules are large, poorly diffusible into areas of bulky disease, and highly immunogenic, rendering repeated infusions difficult. These advantages and disadvantages must be carefully considered in the application of mAb to the treatment of hematopoietic cancers.

Keywords

Toxicity Lymphoma Leukemia Radionuclide Pseudomonas 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Scheinberg DA (1991). Current applications of monoclonal antibodies to the therapy of hematopoietic neoplasms. Curr Opin Immunol pp. 679–685.Google Scholar
  2. 2.
    Houghton AN, Scheinberg DA (1986). Monoclonal antibodies: potential applications to the treatment of cancer. Semin Oncol 13: 165–179.PubMedGoogle Scholar
  3. 3.
    DiMaggio JJ, Scheinberg DA, Houghton AN (1989). Monoclonal antibodies for the treatment of cancer. In Cancer Chemotherapy and Biological Response Modifiers Annual, vol. 2, Longo D (ed). Elsevier Medical Publishers: Amsterdam, pp. 177–203.Google Scholar
  4. 4.
    Foon KA, Todd RF III (1986) Immunologic classification of leukemia and lymphoma. Blood 68: 1–31.PubMedGoogle Scholar
  5. 5.
    Carel J-C, Myones BL, Frazier B, Holers VM (1990). Structural requirements for C3d,g/ Epstein-Barr Virus Receptor (CR2/CD21) ligand binding, internalization, and viral infection. The J Biol Chem 265: 12293–12299.Google Scholar
  6. 6.
    Knapp W (ed) (1989). Leukocyte Typing IV. White Cell Differentiation Antigens. Oxford University Press: Oxford.Google Scholar
  7. 7.
    Civin CI (1990). Human monomyeloid cell membrane antigens. Exp Hematol 18: 461–467.PubMedGoogle Scholar
  8. 8.
    Ball ED, Bernier GM, Cornwell GG (1983). Monoclonal antibodies to myeloid differentiation antigens: In vivo studies of three patients with acute myelogenous leukemia. Blood 62: 1203–1210.PubMedGoogle Scholar
  9. 9.
    Ball ED, Mills LE, Coughlin CT, Beck JR, Cornwell GG III (1986). Autologous bone marrow transplantation in acute myelogenous leukemia: In vivo treatment with myeloid cell-specific monoclonal antibodies. Blood 68: 1311–1315.PubMedGoogle Scholar
  10. 10.
    Defabritius P, Ferro D, Sandrelli A, Tarella C, Meloni G, Pulsoni A, Pregno P, Badoni R, DeFelice L, Gallo E, Amadori S, Mandelli F, Pileri A (1989). Monoclonal antibody purging and autologous bone marrow transplantation in acute myelogenous leukemia in complete remission. Bone Marrow Transplant 4: 669–674.Google Scholar
  11. 11.
    Ball ED, Mills L, Hurd D, Miller W, Gingrich R (in press). Autologous bone marrow transplantation for acute myeloid leukemia using monoclonal antibody-purged bone marrow.Google Scholar
  12. 12.
    Fanger MW, Ball ED, Guyre PM, Fisher J, Dinces NB (1991). The use of bispecific antibody in the therapy of tumors. Proc Am Assoc Cancer Res 32: 489–490.Google Scholar
  13. 13.
    Griffin JD, Linch D, Sabbath F, Larcam P, Schlossman SF (1984). A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8: 521–534.PubMedCrossRefGoogle Scholar
  14. 14.
    Andrews RB, Torok-Storb B, Bernstein ID (1983). Myeloid associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 62: 124.PubMedGoogle Scholar
  15. 15.
    Tanimoto M, Scheinberg DA, Cordon-Cardo C, Huie D, Clarkson BD, Old LJ (1989). Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia 3: 339–348.PubMedGoogle Scholar
  16. 16.
    Scheinberg DA, Tanimoto M, McKenzie S, Strife A, Old LJ, Clarkson BD (1989). Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia. Leukemia 3: 440–445.PubMedGoogle Scholar
  17. 17.
    Scheinberg DA, Strand M (1982). Leukemic cell targeting and therapy by monoclonal antibody in a mouse model system. Cancer Res 42: 44–49.PubMedGoogle Scholar
  18. 18.
    Shawler DL, Miceli MC, Wormsley SB, Royston I, Dillman RO (1984). Induction of in vitro and in vivo antigenic modulation by the anti-human T-cell monoclonal antibody T101. Cancer Res 44: 5921–5927.PubMedGoogle Scholar
  19. 19.
    Hertler AA, Frankel AE (1989). Immunotoxins: A clinical review of their use in the treatment of malignancies. J Clin Oncol 7: 1932–1942.PubMedGoogle Scholar
  20. 20.
    Scheinberg DA, Strand M, Gansow OA (1982). Tumor imaging with radioactive metal chelate conjugated monoclonal antibodies. Science 215: 1511–1513.PubMedCrossRefGoogle Scholar
  21. 21.
    Gansow OA, Watcher R, Link DC, Friedman AM, Seevers RH, Anderson W, Scheinberg DA, Strand M (1984). Generator produced Bi-212 chelated to chemically modified monoclonal antibodies for use in radiotherapy. In Radionuclide Generators: New Systems for Nuclear Medicine Applications, Knapp FF, Butler TA (eds). American Chemical Society: Washington, DC.Google Scholar
  22. 22.
    Sastry KSR, Rao DV (1984). Dosimetry of low energy electrons. In Physics of Nuclear Medicine, Rao DV, Chandra R, Graham MC (eds). American Association of Physicists in Medicine.Google Scholar
  23. 23.
    Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, Feirt N, Finn RD, Clarkson BD, Gee TS, Larson SM, Oettgen HF, Old LJ (1991). A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 9: 478–490.PubMedGoogle Scholar
  24. 24.
    Schwartz MA, Lovett DR, Redner A, et al. (1991). Leukemia cytoreduction and marrow ablation after therapy with 131I labeled monoclonal antibody M195 for acute myelogenous leukemia (AML). Proc Am Soc Clin Oncol.Google Scholar
  25. 25.
    Scheinberg DA, Graham MC, Divgi CR, Lovett DR, Schwartz MA, Finn RD, Redner A, Andreeff MA, Gee TS, Oettgen HF, Larson SM, Old LJ (1991). Myelogenous leukemia and bone marrow ablation with antibody-targeted iodine-131. Dosimetry and pharmacology. Proc Am Assoc Cancer Res 32: 259.Google Scholar
  26. 26.
    Rettig WJ, Condon-Cardo C, Ng JSC, Oettgen HF, Old LJ, Lloyd KO (1985). High-molecular-weight glycoproteins of human teratocarcinoma denned by monoclonal antibodies to carbohydrate determinants. Cancer Res 45: 815–821.PubMedGoogle Scholar
  27. 27.
    Gorin NC, Aegerter P, Auvert B, et al. (1990). Autologous bone marrow transplantation for acute myeloid leukemia in first remission: A European survey of the role of marrow purging. Blood 75: 1606–1614.PubMedGoogle Scholar
  28. 28.
    Peiper SC, LeBoeuf RD, Hughes CB, Prasthofer EF, Borowitz MJ, Dewutter-Dambuyant C, Katz DR, Walker WS, Ashmun RA, Look AT (1989). Report on the CD33 cluster workshop: Biochemical and genetic characterization of gp67. In: Leucocyte Typing IV White Cell Differentiation Antigens, Knapp W, Dörken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne EAGKr (eds) Oxford University Press: Oxford, pp. 814–818.Google Scholar
  29. 29.
    Peiper SC, Ashmun RA, Look AT (1988). Molecular cloning, expression, and chromosomal localization of a human clone encoding the CD33 myeloid differentiation antigen. Blood 72: 314–321.PubMedGoogle Scholar
  30. 30.
    Simmons D, Seed B (1988). Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. J Immunol 141: 2797–2800.PubMedGoogle Scholar
  31. 31.
    Andrews RG, Takahashi M, Segal GM, Powell JS, Bernstein ID, Singer JW (1986). The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 68: 1030–1035.PubMedGoogle Scholar
  32. 32.
    Lemoli RM, Gulati SC, Scheinberg DA, Gasparetto C, Moore MAS, Clarkson BD, Gee T (1991). Autologous bone marrow transplantation in acute myelogenous leukemia (AML): in vivo treatment with myeloid-specific monoclonal antibodies (MoAbs) and drugs in combination. Blood 77: 1829–1836.PubMedGoogle Scholar
  33. 33.
    Sabbath KD, Ball ED, Larcom P, Davis RB, Griffin JD (1985). Heterogeneity of clonogenic cells in acute myeloblastic leukemia. J Clin Invest 75: 746–753.PubMedCrossRefGoogle Scholar
  34. 34.
    Bernstein ID, Singer JW, Andrews RG, Keeting A, Powell JS, Bjornson BH, Cuttner J, Najfeld V, Reaman G, Raskind W, Sutton DMC, Fialkow PJ (1987). Treatment of acute myeloid leukemia cells in vitro with monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest 79: 1153–1159.PubMedCrossRefGoogle Scholar
  35. 35.
    Robertson MJ, Griffin J, Soeffer R, Anderson K, Freedman AS, Nadler LM, Ervin T, Ritz J (1990). Hematologic engraftment in patients with AML after ablative therapy and reinfusion of anti-MY9 (Anti-CD33) antibody purged autologous bone marrow. Proc Am Soc Hematol:283A.Google Scholar
  36. 36.
    Hudson AM, Makrynikola V, Kabral A, Bradstock KF (1989). Immunophenotypic analysis of clonogenic cells in acute lymphoblastic leukemia using an in vitro colony assay. Blood 74: 2112–2120.PubMedGoogle Scholar
  37. 37.
    Divgi CR, Minniti JG, Old LJ, Scheinberg DA (1989). Internalization of radiolabeled monoclonal antibody (mAb) into specific cells: Effect of radionuclide and antibody form. Cancer Res (Suppl) 30: 404a.Google Scholar
  38. 38.
    Stiff PJ, Schulz WB, Bishop M, Marks L (1991). Anti-CD33 monoclonal antibody and etoposide/cytosine arabinoside combination for the ex vivo purification of bone marrow in acute nonlymphocytic leukemia. Blood 77: 355–362.PubMedGoogle Scholar
  39. 39.
    Roy DC, Griffin JD, Belvin M, Blättler, Lambert JM, Ritz J (in press). Anti-MY9-Blocked-Ricin: An immunotoxin for selective targeting of acute myeloid leukemia cells. Blood.Google Scholar
  40. 40.
    Wiesneiwski D, Strife A, Arlin Z, Knowles R, Lambek C, Gulati S, McHendry B, McKenzie S, Clarkson B (1989). Analysis of the individual and combined reactivities of monoclonal antibodies H25, H366, and MY9 with normal progenitor cells and blast cells from patients with acute myeloblastic leukemia. Leukemia 3: 446–452.Google Scholar
  41. 41.
    Applebaum FR, Matthews DC, Eary J, Fisher L, Press O, Martin P, Durack L, Badger C, Bernstein I (1990). Use of radioiodinated anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for AML. Proc Am Soc Hematol 76: 526a.Google Scholar
  42. 42.
    Hale G, Dyer MJS, Clark MJ, et al. (1988). Remission induction in non-Hodgkin lymphoma with the reshaped human monoclonal antibody CAMPATH-1H. Lancet 2: 1394–1399.PubMedCrossRefGoogle Scholar
  43. 43.
    Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA (1989). A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86: 10029–10033.PubMedCrossRefGoogle Scholar
  44. 44.
    Co MS, Avdalovic NM, Caron PC, Bull MK, Avdalovic MV, Scheinberg DA, Queen C (in press). Chimeric and humanized antibodies with specificity for the CD33 antigen. J Immunol.Google Scholar
  45. 45.
    Caron PC, Co MS, Bull MK, Avdalovic NM, Queen C, Scheinberg DA (submitted). Humanized M195 (anti-CD33) monoclonal antibodies: Potential for therapy of myelogenous leukemia.Google Scholar
  46. 46.
    Hank JA, Robinson RR, Surfus J, Mueller BM, Reisfeld RA, Cheung N-K, Sondel PM (1990). Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 50: 5234–5239.PubMedGoogle Scholar
  47. 47.
    Munn DH, Cheung N-KV (1990). Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor. J Exp Med 172: 231–237.PubMedCrossRefGoogle Scholar
  48. 48.
    Vaickus L, Biddle W, Cemerlic D, Foon KA (1990). Interferon gamma augments Lym-1 dependent granulocyte-mediated tumor cells lysis. Blood 75: 2408–2416.PubMedGoogle Scholar
  49. 49.
    Bianchi AC, Heslop HE, Veys P, Macey M, Holland, Prentice HG, Brenner MK (1989). Enhancement of monoclonal antibody dependent cell mediated cytotoxicity by IL2 and GM-CSF. Br J Heamatol 73: 468–474.CrossRefGoogle Scholar
  50. 50.
    Ruegg CL, Anderson-Berg WT, Brechbiel MW, Mirzadeh S, Gansow OA, Strand M (1990). Improved in vitro stability and tumor targeting of Bismuth-labeled antibody. Cancer Res 50: 4221–4226.PubMedGoogle Scholar
  51. 51.
    Kassis AI, Adelstein SJ, Haycock C, Sastry KRS (1980). Radiotoxicity of Se-75 and S-35: Theory and application to a cellular model. Radiat Res 84: 407–425.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • David A. Scheinberg

There are no affiliations available

Personalised recommendations